恩替卡韦联合利拉鲁肽治疗乙肝肝硬化伴肝源性糖尿病患者的临床疗效和安全性研究

目的 观察恩替卡韦联合利拉鲁肽治疗乙肝肝硬化伴肝源性糖尿病患者的临床疗效和安全性.方法 选取2018年5月～2019年5月鄂尔多斯市中医医院收治的100例乙肝肝硬化伴肝源性糖尿病患者为研究对象,以随机数表法分为试验组和对照组,每组50例.试验组患者用恩替卡韦联合利拉鲁肽治疗,对照组患者用利拉鲁肽治疗.分析治疗前后患者的...

Study on the clinical efficacy and safety of entecavir combined with liraglutide in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes

Objective To observe the clinical effi cacy and safety of entecavir combined with liraglutide in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes.Methods One hundred patients with hepatitis B cirrhosis and liver-derived diabetes were divided into a test group(routine treatment+Entecavir+liraglutide treatment)and a control group(routine treatment and liraglutide)with a random number table method,each with 50 cases.We were admitted to our hospital from May 2018 to May 2019.By analyzing the liver function,blood glucose level,and incidence of adverse reactions of patients before and after treatment,the clinical effi cacy and safety of diff erent drugs in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes were evaluated.Results After treatment,the levels of direct bilirubin(DBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBiL)of the subjects showed a downward trend,and the test group was signifi cantly lower than the control group(P<0.05);After treatment,the levels of glycosylated hemoglobin(HbA1c),fasting blood glucose(FBG),and 2 h postprandial blood glucose(2 hPBG)of the subjects showed a downward trend.The test group was signifi cantly lower than the control group(P<0.05).There was no signifi cant diff erence in incidence ofadverse reactions between the two groups(P>0.05).Conclusion The administration of entecavir and liraglutide can reduce the adverse reactions and blood glucose,and improve the antiviral eff ects,liver function and treatment safety.This method is worthy of clinical application and promotion.